US 12,070,500 B2
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
Elizabeth E. Evans, Bloomfield, NY (US); Ernest S. Smith, W. Henrietta, NY (US); and Maurice Zauderer, Pittsford, NY (US)
Assigned to VACCINEX, INC., Rochester, NY (US)
Filed by Vaccinex, Inc., Rochester, NY (US)
Filed on Jun. 29, 2021, as Appl. No. 17/362,020.
Application 17/362,020 is a continuation of application No. 16/392,451, filed on Apr. 23, 2019, granted, now 11,078,295.
Application 16/392,451 is a continuation of application No. 15/666,133, filed on Aug. 1, 2017, granted, now 10,526,414, issued on Jan. 7, 2020.
Application 15/666,133 is a continuation of application No. 14/892,099, granted, now 9,828,435, issued on Nov. 28, 2017, previously published as PCT/US2014/043466, filed on Jun. 20, 2014.
Claims priority of provisional application 61/907,845, filed on Nov. 22, 2013.
Claims priority of provisional application 61/884,771, filed on Sep. 30, 2013.
Claims priority of provisional application 61/874,241, filed on Sep. 5, 2013.
Claims priority of provisional application 61/839,170, filed on Jun. 25, 2013.
Prior Publication US 2021/0324103 A1, Oct. 21, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); A61K 31/675 (2006.01); A61K 35/15 (2015.01); A61K 38/20 (2006.01); A61K 39/00 (2006.01); C07K 14/47 (2006.01); C07K 14/705 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); C12N 5/0783 (2010.01); G01N 33/50 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 39/3955 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); A61K 31/675 (2013.01); A61K 35/15 (2013.01); A61K 38/2013 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/572 (2013.01); C07K 14/4705 (2013.01); C07K 14/70596 (2013.01); C07K 16/18 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C12N 5/0638 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/998 (2013.01); G01N 33/5094 (2013.01)] 13 Claims
 
1. A method for inhibiting, delaying or reducing tumor growth in a subject with cancer, comprising administering to the subject a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of an anti-Lymphocyte Activation Gene 3 (LAG-3) antibody or antigen-binding fragment thereof; or a combination of an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D), an anti-LAG-3 antibody or antigen-binding fragment thereof, and another antibody or antigen-binding fragment thereof that inhibits an immune checkpoint blockade;
wherein the antibody or antigen-binding fragment thereof that specifically binds to SEMA4D comprises a variable heavy chain (VH) comprising VHCDRs 1-3 comprising SEQ ID NO: 6, 7, and 8, respectively, and a variable light chain (VL) comprising VLCDRs 1-3 comprising SEQ ID NO: 14, 15, and 16, respectively; and
wherein administration of the combination results in enhanced therapeutic efficacy relative to administration of the anti-SEMA4D antibody or the anti-LAG-3 antibody alone.